Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | METAP2 | P50579 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6544062 | 0.79 | PDPK1 (0.66) | PDPK1DYRK1AAPPMETAP2ACHE | |
| SCHEMBL1748098 | 0.79 | ALDH1A1 (0.66) | ALDH1A1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL29951795 | 0.78 | PDPK1 (0.59) | PDPK1DYRK1AAPPMETAP2ACHE | |
| Iodide SCHEMBL1770191 | 0.78 | ALDH1A1 (0.63) | ALDH1A1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL17987894 | 0.76 | PDPK1 (0.61) | PDPK1DYRK1AAPPMETAP2ACHE | |
| SCHEMBL5820155 | 0.76 | PDPK1 (0.61) | PDPK1DYRK1AAPPMETAP2ACHE | |
| SCHEMBL3622776 | 0.76 | PDPK1 (0.61) | PDPK1DYRK1AAPPMETAP2ACHE | |
| SCHEMBL74065 | 0.76 | PDPK1 (1.00) | PDPK1DYRK1AAPPMETAP2ACHE | |
| SCHEMBL534640 | 0.76 | ALDH1A1 (0.52) | PDPK1ALDH1A1RAB9ANPC1KMT2A | |
| SCHEMBL2615997 | 0.76 | LMNA (0.61) | ALDH1A1RAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023020534-A1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-02-23 | — | — | WO | disclosed |
| US-20230046569-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-02-16 | — | — | US | disclosed |
| US-11324729-B2 | NSD family inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-05-10 | — | — | US | disclosed |
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| CN-107829094-B | High temperature resistant corrosion inhibitor and preparation method thereof | 中国石油化工股份有限公司 | 2019-10-11 | — | — | CN | disclosed |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
| US-20190183865-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-06-20 | — | — | US | disclosed |
| WO-2019113469-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2018069863-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-19 | — | — | WO | disclosed |
| CN-107829094-A | Sulfur resistive high temperature resistant corrosion inhibitor and preparation method thereof | 中国石油化工股份有限公司 | 2018-03-23 | — | — | CN | disclosed |
| US-20070123543-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | US | disclosed |
| EP-1699803-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005054249-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | WO | disclosed |
| EP-0808838-B1 | Sulfur-containing heterocyclic bradykinin antagonists, processes for their production and use thereof | HOECHST AG (DE) | 2003-10-22 | — | — | EP | disclosed |
| US-5834500-A | ADMINISTERING DERIVATIVES OF BENZYLOXY-BENZOTHIAZENES TO CONTROL RELEASE OF PROSTAGLANDINS, LEUKOTRIENES, HISTAMINES, TACHYKININS, THROMBOXANES; ANALGESICS, ANTIASTHMATIC, ANTIINFLAMMATORY, WOUND HEALING AND ANTITUMOR AGENTSAGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-11-10 | — | — | US | disclosed |
| CN-1169992-A | Sulfur-containing heterocyclic brad-ykinin antagcnists, process for their preparation and their use | HOECHST AG (DE) | 1998-01-14 | — | — | CN | disclosed |
| EP-0808838-A1 | Sulfur-containing heterocyclic bradykinin antagonists, processes for their production and use thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | HPGDS, PTGDR, PTGER1 | PDPK1 2065/4885DYRK1A 3195/4885APP 2225/4885 |
| US-20230046569-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | NSD3, NSD2, NSD1 | PDPK1 4206/4885DYRK1A 4271/4885APP 3921/4885 |
| US-20070123543-A1 | Novel compounds | C1R, CHRM2, CHRM1 | PDPK1 3965/4885DYRK1A 2254/4885APP 2628/4885 |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | HPGDS, PTGDR, PTGER1 | PDPK1 2065/4885DYRK1A 3195/4885APP 2225/4885 |
| US-11324729-B2 | NSD family inhibitors and methods of treatment therewith | NSD3, NSD2, NSD1 | PDPK1 4206/4885DYRK1A 4271/4885APP 3921/4885 |
| US-20190183865-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | NSD3, NSD2, NSD1 | PDPK1 4206/4885DYRK1A 4271/4885APP 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.